How Genomic Biomarkers Are Changing Cancer Treatment

Genomic biomarkers let oncologists match therapy to tumor DNA. Hoadley et al. (2014) showed that cancers of the same organ separate into molecular subtypes with distinct biology.¹ The clinical question is never "should we do genomics?" but "which alteration-drug pairing has trial evidence in this line of therapy?"

Predictive Biomarkers With Pivotal Trial Evidence

EGFR-mutant NSCLC. Mok et al. (2009) randomized EGFR-mutation-positive patients to gefitinib or chemotherapy. Progression-free survival favored gefitinib in mutation-positive disease (HR 0.48; 95% CI 0.36 to 0.64).² Soria et al. (2018) later showed first-line osimertinib improved PFS versus gefitinib/erlotinib (median 18.9 vs 10.2 months; HR 0.46).³ Ramalingam et al. (2020) reported median overall survival 38.6 vs 31.8 months.⁴ These results bind to EGFR sensitizing mutations and TKI generation, not to every lung adenocarcinoma.

BRAF V600E melanoma. Chapman et al. (2011) compared vemurafenib with dacarbazine in previously untreated metastatic melanoma with BRAF V600E. Confirmed response rates were 48% versus 5%.⁵ Cutaneous squamous-cell proliferations are a known class toxicity and should be monitored.

Germline BRCA and PARP inhibition. Robson et al. (2017) randomized HER2-negative metastatic breast cancer patients with germline BRCA mutations to olaparib or physician's-choice chemotherapy. Median PFS was 7.0 versus 4.2 months (HR 0.58).⁶ PARP benefit is tied to homologous recombination deficiency biology, not BRCA status alone in every tumor type.

HER2-positive breast cancer. Slamon et al. (2001) established trastuzumab plus chemotherapy benefit in HER2-positive metastatic disease.⁷ Modern HER2-directed combinations have their own trial programs; literature review must stay drug- and line-specific.

MSI-H / dMMR and checkpoint blockade. Marabelle et al. (2022) reported pembrolizumab in KEYNOTE-158 cohort K (non-colorectal MSI-H/dMMR tumors): objective response rate 30.8% (95% CI 25.8% to 36.2%).⁸ MSI is a predictive biomarker in defined immunotherapy settings, not a universal immunotherapy switch.

Tumor Mutational Burden as an Immunotherapy Biomarker

Samstein et al. (2019) analyzed 1,662 advanced cancer patients treated with immune checkpoint inhibitors whose tumors underwent MSK-IMPACT sequencing. Higher somatic TMB (top 20% within each histology) associated with better overall survival (HR 0.52 versus bottom 80%).¹⁰ Critically, TMB cutpoints that correlated with benefit varied markedly between cancer types. There is no single universal "high TMB" threshold across histologies.

Read our blog on immunotherapy biomarkers to learn more about PD-L1, TMB, and MSI evidence boundaries.

Resistance Mechanisms: Why Serial Genotyping Matters

Targeted therapy selects for resistant clones. Leonetti et al. (2019) review osimertinib resistance in EGFR-mutant NSCLC: EGFR C797S, MET or HER2 amplification, RAS-MAPK or PI3K pathway activation, novel fusions, and histologic transformation.¹¹ Resistance spectra differ between first-line and post-TKI osimertinib, reflecting different selection pressures.

Simon (2013) stresses that prognostic markers (outcome regardless of treatment) must not be marketed or protocolized as predictive without treatment-interaction evidence.¹² Misclassification breaks companion diagnostic logic and enrichment trials.

Liquid biopsy can capture emergent alterations at progression. Read our blog on liquid biopsy biomarkers to learn more about circulating tumor DNA monitoring evidence.

From Panel Reports to Protocol Decisions

Before ordering NGS or locking inclusion criteria, teams should map published evidence for each alteration-drug pair:

• Was benefit shown in first-line, adjuvant, or post-progression settings?
• Which assay and cutoff defined positivity in pivotal trials?
• Do resistance papers for that drug class list mechanisms relevant to your cohort?

Before tumor boards or protocol synopses lock inclusion criteria, teams often need a cited map of alteration-drug evidence. Literature tools like Motif can export PMID-linked associations across biomedical entity types and cross-reference curated databases; assay validation and treatment decisions still sit with your clinical team.

Common Failure Modes in Genomic Biomarker Programs

• Ordering broad NGS panels without a therapy-linked question for each actionable alteration
• Applying TMB cutoffs from one histology to another without indication-specific validation literature
• Treating germline BRCA status as sufficient for PARP benefit without tumor HRD context in some settings
• Ignoring resistance papers when planning serial biopsy or liquid biopsy at progression
• Relabeling prognostic markers as predictive without treatment interaction evidence (Simon, 2013)

Read our blog on personalized medicine biomarker analysis to learn more about basket trials, master protocols, and BEST categories.

References

1. Hoadley, K.A., et al. (2014). Multiplatform analysis of 12 cancer types. Cell, 158(4), 929-944. PMID: 24120142
2. Mok, T.S., et al. (2009). Gefitinib or chemotherapy for EGFR-mutated NSCLC. NEJM, 361(10), 947-957. PMID: 19692680
3. Soria, J.C., et al. (2018). Osimertinib in untreated EGFR-mutated advanced NSCLC. NEJM, 378(2), 113-125. PMID: 29151359
4. Ramalingam, S.S., et al. (2020). Overall survival with osimertinib in untreated EGFR-mutated advanced NSCLC. NEJM, 382(1), 41-50. PMID: 31751012
5. Chapman, P.B., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. NEJM, 364(26), 2507-2516. PMID: 21639808
6. Robson, M., et al. (2017). Olaparib for metastatic breast cancer with germline BRCA mutation. NEJM, 377(6), 523-533. PMID: 28578601
7. Slamon, D.J., et al. (2001). Trastuzumab plus chemotherapy for HER2-positive breast cancer. NEJM, 344(11), 783-792. PMID: 11248153
8. Marabelle, A., et al. (2022). Pembrolizumab in MSI-H cancers: KEYNOTE-158 update. Ann Oncol, 33(10), 1032-1042. PMID: 35680043
9. Zehir, A., et al. (2017). MSK-IMPACT clinical sequencing. JCO, 35(18), 2011-2017. PMID: 28481382
10. Samstein, R.M., et al. (2019). Tumor mutational load predicts survival after immunotherapy. Nat Genet, 51(2), 202-206. PMID: 30643254
11. Leonetti, A., et al. (2019). Resistance mechanisms to osimertinib in EGFR-mutated NSCLC. Br J Cancer, 121(9), 725-737. PMID: 31564718
12. Simon, R.M. (2013). Genomic biomarkers in predictive medicine. Clin Chem, 59(1), 37-46. PMID: 23818349